Pelthos Therapeutics Inc. Form PRE 14A: Preliminary proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-08-07: Form PRE 14A; Period of report 2026-09-29; Description PRE 14A; Document pths-20260807.htm.
- 2025-11-14: Form PRE 14A; Period of report 2025-11-14; Description Preliminary proxy statement; Document g085012_pre14a.htm.
- 2024-09-09: Form PRE 14A; Period of report 2024-10-22; Description PRE 14A; Document ny20034854x1_pre14a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-08-07 | PRE 14A | 2026-09-29 | PRE 14A | pths-20260807.htm |
| 2025-11-14 | PRE 14A | 2025-11-14 | Preliminary proxy statement | g085012_pre14a.htm |
| 2024-09-09 | PRE 14A | 2024-10-22 | PRE 14A | ny20034854x1_pre14a.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |